A Bio-Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Chimeric antigen receptor NK (CAR-NK) cell therapy shows promise for advanced cancers.
• Limited tumor cell antigen expression hinders NK cell therapy efficacy.
• Tumor heterogeneity presents a significant challenge in cancer treatment.

Purpose of the Study:

• To develop a nanomedicine strategy to enhance tumor cell antigen expression for improved NK cell recognition.
• To create a universal approach for stable and controlled antigen presentation on tumor cells.
• To overcome limitations in current NK cell therapy for solid tumors.

Main Methods:

• Developed the "illuminate tumor homogenization antigen properties" (ITHAP) strategy using bio-liposomes (Pt@PL-IgG).
• Pt@PL-IgG combines platelet membranes, liposomes, NK-activatable IgG antibodies, and cisplatin.
• Utilized membrane fusion properties for IgG implantation and platelet membrane-driven tumor targeting.

Main Results:

• Pt@PL-IgG successfully targeted tumor cells and implanted IgG antibodies.
• NK cell-induced pyroptosis and Pt-DNA complex triggered significant interferon (IFN) secretion.
• Established a synthase-stimulator of interferon genes (STING)-IFN positive immune microenvironment.

Conclusions:

• Anchoring cancer cells with NK-activatable target antigens is a promising strategy.
• The ITHAP approach significantly enhances immune recognizability of tumor cells.
• This method offers a potential solution for therapeutic challenges posed by tumor heterogeneity.